| Dr Andrew Kant Patel, MD | |
|
2222 Nw Lovejoy St Ste 607, Portland, OR 97210-5104 | |
| (503) 222-3638 | |
| Not Available |
| Full Name | Dr Andrew Kant Patel |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 19 Years |
| Location | 2222 Nw Lovejoy St Ste 607, Portland, Oregon |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275749152 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | A97587 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Legacy Good Samaritan Medical Center | Portland, OR | Hospital |
| Providence St Vincent Medical Center | Portland, OR | Hospital |
| Legacy Emanuel Medical Center | Portland, OR | Hospital |
| Providence Portland Medical Center | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pdxent And Audiology Medical Group Pc | 8820397086 | 6 |
News Archive
Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.
For cardiologists, coronary artery disease is the most important presentation of atherosclerosis. Patients with coronary artery disease may also have symptomatic or asymptomatic atherosclerosis in other vascular areas (peripheral artery disease).
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Jonathan Goldman, M.D., Premiere Oncology will present interim results from a Phase 2 trial of ganetespib in non-small cell lung cancer at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
Breakthrough innovation specialist Cambridge Consultants today announced a watershed moment for intravascular surgery, with the demonstration of a single-use, high-definition miniature camera. Called ‘Leap', the technology allows a digital view inside veins and arteries for the first time.
Children diagnosed with sleep-disordered breathing appear to sleep better and have improved behavior following removal of their tonsils and adenoids, according to a report in the October issue of Archives of Otolaryngology-Head & Neck Surgery.
› Verified 3 days ago
| Entity Name | Pdxent And Audiology Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578923751 PECOS PAC ID: 8820397086 Enrollment ID: O20160422001012 |
News Archive
Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.
For cardiologists, coronary artery disease is the most important presentation of atherosclerosis. Patients with coronary artery disease may also have symptomatic or asymptomatic atherosclerosis in other vascular areas (peripheral artery disease).
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Jonathan Goldman, M.D., Premiere Oncology will present interim results from a Phase 2 trial of ganetespib in non-small cell lung cancer at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
Breakthrough innovation specialist Cambridge Consultants today announced a watershed moment for intravascular surgery, with the demonstration of a single-use, high-definition miniature camera. Called ‘Leap', the technology allows a digital view inside veins and arteries for the first time.
Children diagnosed with sleep-disordered breathing appear to sleep better and have improved behavior following removal of their tonsils and adenoids, according to a report in the October issue of Archives of Otolaryngology-Head & Neck Surgery.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Kant Patel, MD 2222 Nw Lovejoy St Ste 607, Portland, OR 97210-5104 Ph: (503) 222-3638 | Dr Andrew Kant Patel, MD 2222 Nw Lovejoy St Ste 607, Portland, OR 97210-5104 Ph: (503) 222-3638 |
News Archive
Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.
For cardiologists, coronary artery disease is the most important presentation of atherosclerosis. Patients with coronary artery disease may also have symptomatic or asymptomatic atherosclerosis in other vascular areas (peripheral artery disease).
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Jonathan Goldman, M.D., Premiere Oncology will present interim results from a Phase 2 trial of ganetespib in non-small cell lung cancer at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
Breakthrough innovation specialist Cambridge Consultants today announced a watershed moment for intravascular surgery, with the demonstration of a single-use, high-definition miniature camera. Called ‘Leap', the technology allows a digital view inside veins and arteries for the first time.
Children diagnosed with sleep-disordered breathing appear to sleep better and have improved behavior following removal of their tonsils and adenoids, according to a report in the October issue of Archives of Otolaryngology-Head & Neck Surgery.
› Verified 3 days ago
David Wei Kuo Lin, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 3600 N Interstate Ave, Interstate Medical Office Central, Portland, OR 97227 Phone: 503-331-6085 | |
Mr. Michael Lee Mcdonald, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 10101 Se Main St, # 2004, Portland, OR 97216 Phone: 503-257-3204 Fax: 503-255-7208 | |
Dr. Duane Allen Lundeberg, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 2222 Nw Lovejoy St, Suite #622, Portland, OR 97210 Phone: 503-229-8455 Fax: 503-229-7028 | |
Brian Jacob Stater, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 9155 Sw Barnes Rd Ste 536, Portland, OR 97225 Phone: 503-935-8100 Fax: 503-935-8110 | |
Dr. Edsel Uisuk Kim, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 9155 Sw Barnes Rd Ste 536, Portland, OR 97225 Phone: 503-935-8100 Fax: 503-935-8110 | |
James Isaac Cohen, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 3181 Sw Sam Jackson Park Rd, Ohsu Pv-01, Portland, OR 97239 Phone: 503-494-5355 Fax: 503-494-4631 | |
Dr. Larry Richard Thomas, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2222 Nw Lovejoy St, Suite #622, Portland, OR 97210 Phone: 503-229-8455 Fax: 503-229-7028 |